Bladder cancer (BC) is one of the most common tumors in the world. Cystoscopy and tissue biopsy are the standard methods in screening and early diagnosis of suspicious bladder lesions. However, they are invasive procedures that may cause pain and infectious complications. Considering the limitations of both procedures, and the recurrence and resistance to BC treatment, it is necessary to develop a new non-invasive methodology for early diagnosis and multiple evaluations in patients under follow-up for bladder cancer. In recent years, liquid biopsy has proven to be a very useful diagnostic tool for the detection of tumor biomarkers. This non-invasive technique makes it possible to analyze single tumor components released into the peripheral circulation and to monitor tumor progression. Numerous biomarkers are being studied and interesting clinical applications for these in BC are being presented, with promising results in early diagnosis, detection of microscopic disease, and prediction of recurrence and response to treatment.
膀胱癌是全球最常见的肿瘤之一。膀胱镜检查和活组织检查是筛查和早期诊断可疑膀胱病变的标准方法。然而，这些侵入性操作可能引起疼痛和感染性并发症。考虑到这两种方法的局限性，以及膀胱癌治疗中的复发和耐药问题，有必要开发一种新的无创方法，用于膀胱癌随访患者的早期诊断和多次评估。近年来，液体活检已被证明是一种非常有用的肿瘤生物标志物检测诊断工具。这种无创技术使得分析释放到外周循环中的单个肿瘤成分并监测肿瘤进展成为可能。目前正在研究多种生物标志物，并在膀胱癌中展示了具有前景的临床应用，在早期诊断、微小病灶检测以及预测复发和治疗反应方面取得了令人鼓舞的成果。
New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine
肿瘤(癌症)患者之家